Search
Research
Comparative drug screening in NUT midline carcinomaThe NUT midline carcinoma (NMC) is a rare but fatal cancer for which systematic testing of therapy options has never been performed.
Research
Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesisHematopoiesis occurs in a complex bone marrow microenvironment in which bone marrow stromal cells provide critical support to the process through direct cell...
Research
Basal cell carcinomas on sun-protected vs. sun-exposed body sites: A comparison of phenotypic and environmental risk factorsThere are indications that risk factors for BCC may differ according to the anatomic site of the tumour but this is not well understood.
Research
Birthweight and childhood cancer: Preliminary findings from the international childhood cancer cohort consortium (I4C)Background Evidence relating childhood cancer to high birthweight is derived primarily from registry and case-control studies.
Research
Lessons from 50 years of curing childhood leukaemiaOne of the great success stories of modern medicine is undoubtedly the remarkable improvement in outcome for childhood cancer, achieved through the work of...
News & Events
The goal of Project Childrens' Cancer is to discover new, less toxic therapiesThe goal of Project Children's Cancer is to discover new therapies that are more effective and less toxic to fight aggressive cancers in babies and children.
News & Events
More research needed into mums smoking and childhood brain tumoursResearchers from Perth's Telethon Institute are calling for further investigation into a potential link between maternal smoking and childhood brain tumours.
Research
A New Era for PPARγ: Covalent Ligands and Therapeutic ApplicationsPeroxisome proliferator-activated receptor γ (PPARγ) is a prominent ligand-inducible transcription factor involved in adipocyte differentiation, glucose homeostasis, insulin sensitivity, inflammation, and cell proliferation, making it a therapeutic target for diabetes, metabolic syndrome, autoimmune diseases, and cancer.
Research
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trialDue to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.
Research
“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trialsEach year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.